Compare LGVN & GITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGVN | GITS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | South Korea |
| Employees | N/A | 5 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.3M |
| IPO Year | 2021 | N/A |
| Metric | LGVN | GITS |
|---|---|---|
| Price | $1.39 | $1.41 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.25 | N/A |
| AVG Volume (30 Days) | ★ 151.7K | 21.4K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | $46.15 | N/A |
| Revenue Next Year | $396.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.66 |
| 52 Week High | $7.60 | $7.09 |
| Indicator | LGVN | GITS |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 34.70 |
| Support Level | $0.60 | $1.42 |
| Resistance Level | $7.30 | $2.44 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 0.69 | 11.24 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.